EPISODE · Feb 2, 2023 · 19 MIN
GI ASCO 2023 Highlights with Dr. Mark Lewis
from Oncology Brothers: Practice-Changing Cancer Discussions · host Oncology Brothers
Discussing GI ASCO 2023 Highlights - practice changing/informing studies with Dr. Mark Lewis, a Cancer Survivor, Director of GI Oncology at Intermountain Healthcare. SPOTLIGHT - Zolbetuximab with mFOLFOX6 Meets Primary Endpoint NAPOLI3 - Randomized Phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colon cancer MOUNTAINEER - FDA approval of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer SUNLIGHT - Trifluridine/Tipiracil plus Bevacizumab provides benefit in refractory metastatic colorectal cancer Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at [email protected]
What this episode covers
Discussing GI ASCO 2023 Highlights - practice changing/informing studies with Dr. Mark Lewis, a Cancer Survivor, Director of GI Oncology at Intermountain Healthcare. SPOTLIGHT - Zolbetuximab with mFOLFOX6 Meets Primary Endpoint NAPOLI3 - Randomized Phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colon cancer MOUNTAINEER - FDA approval of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer SUNLIGHT - Trifluridine/Tipiracil plus Bevacizumab provides benefit in refractory metastatic colorectal cancer Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at [email protected]
NOW PLAYING
GI ASCO 2023 Highlights with Dr. Mark Lewis
No transcript for this episode yet
Similar Episodes
Mar 31, 2026 ·54m
Mar 27, 2026 ·14m
Mar 24, 2026 ·42m
Mar 20, 2026 ·42m
Mar 17, 2026 ·41m
Mar 13, 2026 ·44m